BACKGROUND & AIMS: Chronic intestinal pseudo-obstruction (CIPO) is characterized by severe intestinal dysmotility that mimics a mechanical subocclusion with no evidence of gut obstruction. We searched for genetic variants associated with CIPO to increase our understanding of its pathogenesis and to identify potential biomarkers. METHODS: We performed whole-exome sequencing of genomic DNA from patients with familial CIPO syndrome. Blood and lymphoblastoid cells were collected from patients and controls (individuals without CIPO); levels of messenger RNA (mRNA) and proteins were analyzed by quantitative reverse-transcription polymerase chain reaction, immunoblot, and mobility shift assays. Complementary DNAs were transfected into HEK293 cells. Expression of rad21 was suppressed in zebrafish embryos using a splice-blocking morpholino (rad21a). Gut tissues were collected and analyzed. RESULTS: We identified a homozygous mutation (p.622, encodes Ala>Thr) in RAD21 in patients from a consanguineous family with CIPO. Expression of RUNX1, a target of RAD21, was reduced in cells from patients with CIPO compared with controls. In zebrafish, suppression of rad21a reduced expression of runx1; this phenotype was corrected by injection of human RAD21 mRNA, but not with the mRNA from the mutated p.622 allele. rad21a Morpholino zebrafish had delayed intestinal transit and greatly reduced numbers of enteric neurons, similar to patients with CIPO. This defect was greater in zebrafish with suppressed expression of ret and rad21, indicating their interaction in the regulation of gut neurogenesis. The promoter region of APOB bound RAD21 but not RAD21 p.622 Ala>Thr; expression of wild-type RAD21 in HEK293 cells repressed expression of APOB, compared with control vector. The gut-specific isoform of APOB (APOB48) is overexpressed in sera from patients with CIPO who carry the RAD21 mutation. APOB48 also is overexpressed in sporadic CIPO in sera and gut biopsy specimens. CONCLUSIONS: Some patients with CIPO carry mutations in RAD21 that disrupt the ability of its product to regulate genes such as RUNX1 and APOB. Reduced expression of rad21 in zebrafish, and dysregulation of these target genes, disrupts intestinal transit and the development of enteric neurons.
BACKGROUND & AIMS:Chronic intestinal pseudo-obstruction (CIPO) is characterized by severe intestinal dysmotility that mimics a mechanical subocclusion with no evidence of gut obstruction. We searched for genetic variants associated with CIPO to increase our understanding of its pathogenesis and to identify potential biomarkers. METHODS: We performed whole-exome sequencing of genomic DNA from patients with familial CIPO syndrome. Blood and lymphoblastoid cells were collected from patients and controls (individuals without CIPO); levels of messenger RNA (mRNA) and proteins were analyzed by quantitative reverse-transcription polymerase chain reaction, immunoblot, and mobility shift assays. Complementary DNAs were transfected into HEK293 cells. Expression of rad21 was suppressed in zebrafish embryos using a splice-blocking morpholino (rad21a). Gut tissues were collected and analyzed. RESULTS: We identified a homozygous mutation (p.622, encodes Ala>Thr) in RAD21 in patients from a consanguineous family with CIPO. Expression of RUNX1, a target of RAD21, was reduced in cells from patients with CIPO compared with controls. In zebrafish, suppression of rad21a reduced expression of runx1; this phenotype was corrected by injection of humanRAD21 mRNA, but not with the mRNA from the mutated p.622 allele. rad21aMorpholinozebrafish had delayed intestinal transit and greatly reduced numbers of enteric neurons, similar to patients with CIPO. This defect was greater in zebrafish with suppressed expression of ret and rad21, indicating their interaction in the regulation of gut neurogenesis. The promoter region of APOB bound RAD21 but not RAD21 p.622 Ala>Thr; expression of wild-type RAD21 in HEK293 cells repressed expression of APOB, compared with control vector. The gut-specific isoform of APOB (APOB48) is overexpressed in sera from patients with CIPO who carry the RAD21 mutation. APOB48 also is overexpressed in sporadic CIPO in sera and gut biopsy specimens. CONCLUSIONS: Some patients with CIPO carry mutations in RAD21 that disrupt the ability of its product to regulate genes such as RUNX1 and APOB. Reduced expression of rad21 in zebrafish, and dysregulation of these target genes, disrupts intestinal transit and the development of enteric neurons.
Authors: C Evangelisti; F Bianco; L M Pradella; A Puliti; A Goldoni; I Sbrana; M Rossi; M Vargiolu; M Seri; G Romeo; V Stanghellini; R de Giorgio; E Bonora Journal: Neurogastroenterol Motil Date: 2012-08-16 Impact factor: 3.598
Authors: Matthew A Deardorff; Jonathan J Wilde; Melanie Albrecht; Emma Dickinson; Stephanie Tennstedt; Diana Braunholz; Maren Mönnich; Yuqian Yan; Weizhen Xu; María Concepcion Gil-Rodríguez; Dinah Clark; Hakon Hakonarson; Sara Halbach; Laura Daniela Michelis; Abhinav Rampuria; Eva Rossier; Stephanie Spranger; Lionel Van Maldergem; Sally Ann Lynch; Gabriele Gillessen-Kaesbach; Hermann-Josef Lüdecke; Robert G Ramsay; Michael J McKay; Ian D Krantz; Huiling Xu; Julia A Horsfield; Frank J Kaiser Journal: Am J Hum Genet Date: 2012-05-24 Impact factor: 11.025
Authors: Judith Marsman; Adam C O'Neill; Betty Rui-Yun Kao; Jenny M Rhodes; Michael Meier; Jisha Antony; Maren Mönnich; Julia A Horsfield Journal: Biochim Biophys Acta Date: 2013-12-07
Authors: Huiling Xu; Kuhendra Balakrishnan; Jordane Malaterre; Matthew Beasley; Yuqian Yan; Jeroen Essers; Esther Appeldoorn; Jonathan M Tomaszewski; Jonathan M Thomaszewski; Melisa Vazquez; Sandra Verschoor; Martin F Lavin; Ivan Bertoncello; Ivan Bertonchello; Robert G Ramsay; Michael J McKay Journal: PLoS One Date: 2010-08-12 Impact factor: 3.240
Authors: F Bianco; S T Eisenman; M G Colmenares Aguilar; E Bonora; P Clavenzani; D R Linden; R De Giorgio; G Farrugia; S J Gibbons Journal: Neurogastroenterol Motil Date: 2018-08-01 Impact factor: 3.598
Authors: Thuy-Linh Le; Louise Galmiche; Jonathan Levy; Pim Suwannarat; Debby Mei Hellebrekers; Khomgrit Morarach; Franck Boismoreau; Tom Ej Theunissen; Mathilde Lefebvre; Anna Pelet; Jelena Martinovic; Antoinette Gelot; Fabien Guimiot; Amanda Calleroz; Cyril Gitiaux; Marie Hully; Olivier Goulet; Christophe Chardot; Severine Drunat; Yline Capri; Christine Bole-Feysot; Patrick Nitschké; Sandra Whalen; Linda Mouthon; Holly E Babcock; Robert Hofstra; Irenaeus Fm de Coo; Anne-Claude Tabet; Thierry J Molina; Boris Keren; Alice Brooks; Hubert Jm Smeets; Ulrika Marklund; Christopher T Gordon; Stanislas Lyonnet; Jeanne Amiel; Nadège Bondurand Journal: J Clin Invest Date: 2021-03-15 Impact factor: 14.808
Authors: Ian A Parish; Lincon A Stamp; Ayla May D Lorenzo; Suzanne M Fowler; Yovina Sontani; Lisa A Miosge; Debbie R Howard; Christopher C Goodnow; Heather M Young; John B Furness Journal: Am J Pathol Date: 2016-07-16 Impact factor: 4.307